Frémont, Marc, El Bakkouri, Karim, Vaeyens, Freya et al. · Experimental and molecular pathology · 2005 · DOI
In ME/CFS, immune cells produce abnormal levels of proteins involved in fighting viral infections. This study found that a protective molecule called 2-5A can shield a key antiviral protein (RNase L) from being broken down by inflammatory enzymes. However, in ME/CFS patients, cells tend to produce smaller versions of 2-5A, which cannot provide this protection, leading to the accumulation of damaged RNase L protein.
This mechanistic study identifies a potential biochemical pathway contributing to ME/CFS pathology: abnormal 2-5A production may fail to protect antiviral enzymes, leading to immune dysregulation. Understanding this mechanism could guide development of targeted therapeutic interventions to restore proper immune function in ME/CFS patients.
This in vitro study does not establish that 2-5A dimer production is the primary cause of ME/CFS, nor does it demonstrate that correcting this abnormality would improve patient symptoms. The study uses cell extracts rather than intact living cells, which may not fully recapitulate in vivo immune dynamics. Correlation between 2-5A oligomer size and RNase L cleavage does not prove causation in the disease process.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →